Zacks Research Issues Pessimistic Estimate for CRL Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Zacks Research reduced their Q4 2024 earnings per share estimates for Charles River Laboratories International in a research note issued on Wednesday, November 27th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $2.47 for the quarter, down from their prior forecast of $2.50. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $10.19 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q1 2025 earnings at $2.42 EPS, Q2 2025 earnings at $2.44 EPS, Q3 2025 earnings at $2.59 EPS, Q4 2025 earnings at $2.62 EPS, FY2025 earnings at $10.07 EPS, Q3 2026 earnings at $2.88 EPS and FY2026 earnings at $11.70 EPS.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the prior year, the business earned $2.72 EPS.

Other research analysts have also recently issued research reports about the company. Baird R W cut Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 8th. Evercore ISI raised their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research report on Monday, November 18th. Barclays decreased their price target on shares of Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. Finally, Robert W. Baird dropped their price objective on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, September 20th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Hold” and an average price target of $214.38.

Charles River Laboratories International Price Performance

CRL stock opened at $199.06 on Monday. Charles River Laboratories International has a 1 year low of $176.48 and a 1 year high of $275.00. The firm has a 50-day moving average of $194.32 and a 200 day moving average of $204.75. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The company has a market cap of $10.18 billion, a P/E ratio of 24.91, a PEG ratio of 5.13 and a beta of 1.38.

Institutional Investors Weigh In On Charles River Laboratories International

A number of large investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its stake in shares of Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after acquiring an additional 3,738,018 shares during the last quarter. State Street Corp grew its holdings in Charles River Laboratories International by 2.0% during the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after purchasing an additional 41,421 shares during the period. Kayne Anderson Rudnick Investment Management LLC increased its position in Charles River Laboratories International by 1.7% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company’s stock worth $394,359,000 after buying an additional 31,359 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Charles River Laboratories International by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock valued at $346,821,000 after buying an additional 509,163 shares in the last quarter. Finally, Earnest Partners LLC lifted its holdings in Charles River Laboratories International by 12.4% during the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock valued at $207,507,000 after purchasing an additional 110,725 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Insider Buying and Selling

In other news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the transaction, the director now directly owns 12,386 shares of the company’s stock, valued at $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International declared that its board has authorized a share repurchase plan on Wednesday, August 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to buy up to 9.6% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).